DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
The report provides an overview of the Chronic Urticaria Or Hives clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Urticaria Or Hives. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Reasons to buy:
- Assists in formulating key business strategies with regards to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials.
-
Facilitates clinical trial assessment of the indication on a global,
regional and country level.
Companies Mentioned:
- Novartis AG
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Dr. Reddy's Laboratories Limited
- J Uriach Y Compania, S.A.
- Faes Farma, SA
- UCB S.A.
- Sun Pharmaceutical Industries Limited
- GlaxoSmithKline Plc
-
Mylan N.V.
For more information visit http://www.researchandmarkets.com/research/vhcfl9/chronic_urticaria
